FDA Staffing: Retirements Account For More Than One-Third Of FY 2023 Departures
Combination of an aging workforce and departures that were delayed by the pandemic are taking a toll on the agency’s current staffing levels, Chief of Staff Julie Tierney says.
You may also be interested in...
Until hiring is completed, the new Office of Therapeutic Products director must head an office and two divisions she supervises in addition to her actual duties.
Nicole Verdun, who had been running the CBER Office of Blood Research and Review, now is director of the center’s Office of Therapeutic Products. She will manage OTP’s growing head count, as well as its increasing workload.
Increases in the consumer price index helped drive some of the user fee increases that will take effect on 1 October, even though personnel costs declined in some FDA programs.